AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news
خواندن متن کامل در استتنیوزبه زبان اصلی، در سایت ناشر باز میشودمتن اصلی (انگلیسی)
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news